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Abstract
Approximately 30% of alleles causing genetic disorders generate premature termination codons (PTCs), which are usually
associated with severe phenotypes. However, bypassing the deleterious stop codon can lead to a mild disease outcome.
Splicing at NAGNAG tandem splice sites has been reported to result in insertion or deletion (indel) of three nucleotides. We
identified such a mechanism as the origin of the mild to asymptomatic phenotype observed in cystic fibrosis patients
homozygous for the E831X mutation (2623G.T) in the CFTR gene. Analyses performed on nasal epithelial cell mRNA
detected three distinct isoforms, a considerably more complex situation than expected for a single nucleotide substitution.
Structure-function studies and in silico analyses provided the first experimental evidence of an indel of a stop codon by
alternative splicing at a NAGNAG acceptor site. In addition to contributing to proteome plasticity, alternative splicing at a
NAGNAG tandem site can thus remove a disease-causing UAG stop codon. This molecular study reveals a naturally
occurring mechanism where the effect of either modifier genes or epigenetic factors could be suspected. This finding is of
importance for genetic counseling as well as for deciding appropriate therapeutic strategies.
Citation: Hinzpeter A, Aissat A, Sondo E, Costa C, Arous N, et al. (2010) Alternative Splicing at a NAGNAG Acceptor Site as a Novel Phenotype Modifier. PLoS
Genet 6(10): e1001153. doi:10.1371/journal.pgen.1001153
Editor: Christopher E. Pearson, The Hospital for Sick Children and University of Toronto, Canada
Received March 1, 2010; Accepted September 9, 2010; Published October 7, 2010
Copyright:  2010 Hinzpeter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from Institut National de la Sante et de la Recherche Medicale (INSERM), association La Pierre Le Bigaut and Vaincre
la Mucoviscidose. AH is the recipient of a post-doctoral fellowship from the French CF association Vaincre la Mucoviscidose. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: pascale.fanen@inserm.fr
Introduction
Premature termination codons (PTCs) are usually associated
with severe phenotypes. However, mild disease outcomes can
occur by at least three different mechanisms [1]. First, translation
can be initiated at an internal start codon located downstream
from the PTC [2]. Second, PTCs can trigger nonsense-mediated
mRNA decay (NMD), a pathway that protects the cell from
aberrant transcripts [3]. Third, nonsense-associated alternative
splicing (NAS) [4] can remove the exon harboring the PTC.
Subtle changes in alternative splicing events have recently been
reported at particular tandem acceptor splice sites, NAGNAG sites
(where N represents any nucleotide) [5–7]. The use of the intron
proximal or distal splice site results in the production of two
distinct isoforms distinguished by three nucleotides (NAG). This
alternative splicing could result in the creation or deletion of a stop
codon [5]. The latter event would thus constitute another
mechanism of PTC removal, but has never been described in
human pathophysiology.
Splice events at short-distance tandem sites are widespread and
contribute to transcriptome and proteome complexity [5].
NAGNAG acceptor motifs are present in 30% of human genes
and several studies based on computational analysis using
expressed sequence tag (EST) databases showed that at least 5%
of human genes contain an experimentally confirmed NAGNAG
tandem site [5]. A subtle splice event associated with Stargardt’s
disease 1, in which a mutation in the ABCA4 gene produced an
indel of one amino acid in 50% of the transcripts from one patient,
has been described [8]. Nonetheless, the involvement of mutations
that alter tandem sites have not been extensively studied in disease
[9]. Therefore, to explore further the effect of mutations located
within a NAGNAG acceptor motif, we studied the cystic fibrosis
transmembrane conductance regulator gene (CFTR). Querying the
Tandem Splice Site DataBase (TassDB), a comprehensive online
database dedicated to recognizing tandem acceptor sites, identified
two NAGNAG motifs in CFTR. Mutations in the CFTR gene,
which encodes a cAMP-regulated Cl
2 channel located at the
apical membrane of epithelial cells, cause cystic fibrosis (CF). CF is
the most common severe autosomal recessive genetic disorder in
Caucasians [10] and affects the physiology of the lung,
gastrointestinal tract, reproductive organs, and sweat glands.
Mutations in the CFTR gene induce a continuum of phenotypes
ranging from mild manifestations with isolated features such as
congenital bilateral absence of the vas deferens (CBAVD), or nasal
polyposis, to severe disease symptoms. Therefore, CF is a good
model to identify novel modifier mechanisms [11]. Here, we show
that alternative splicing at a tandem acceptor site removes a
premature UAG stop codon and leads to synthesis of a functional
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phenotype detected in several patients.
Results/Discussion
Family pedigree
In this study, we focused on the rare E831X mutation
(2623G.T) which affects the first nucleotide of exon 14a which
forms part of one of the two NAGNAG acceptor sites detected in
the CFTR gene. We had the opportunity to study a consanguin-
eous family of Turkish origin which included three patients
(Figure 1A) homozygous for the E831X mutation (Figure 1B). To
evaluate the functional consequences of this mutation in a tandem
splice motif, we performed transcript analysis on epithelial cells
obtained from patient III10 (Figure 1A) by nasal brushing, which is
the least invasive technique and provides the most reliable cells to
study CFTR mRNA.
Direct transcript analysis
Mutations that generate PTCs can reduce the steady-state level
of mRNA via nonsense-mediated decay (NMD) [3]. Total RNA
from nasal epithelial cells of patient III10 was first quantified to
evaluate the amount of CFTR transcripts. Quantitative analysis by
real-time PCR was normalized to that of keratin 18 (KRT18), a
marker of ciliated and secretory epithelial cells [12,13]. The results
clearly showed that the level of CFTR mRNA was reduced by half
in the sample from patient III10 compared to three control samples
(48%69% compared to WT, Figure 2A), showing that the CFTR
mRNAs were subject to NMD.
To evaluate the mRNA pattern associated with the 2623G.T
mutation, a semi-quantitative RT-PCR analysis was performed
and the products were analyzed by capillary electrophoresis. In
control samples, two peaks could be detected: a major peak
corresponding to the full-length mRNA (97%60.5%) and a
minor peak corresponding to exon 14a skipping (3%60.5%)
(Figure 2B), a feature of CFTR splicing that has been described
previously [14]. In the patient III10 sample, a more complex
pattern appeared, with the presence of three distinct peaks
(Figure 2B) that were subsequently identified by sequencing: a
major peak corresponding to exon 14a skipping (76%62%)
(Figure 2B and 2C) and two additional peaks corresponding to a
full-length mRNA containing the stop codon (16%62%) and an
mRNA lacking these three nucleotides (8%60.8%) (Figure 2B
and 2D).
Hence, the 2623G.T substitution induced two effects: a
reduced level of full-length mRNA containing the stop codon by
NMD and the generation of additional mRNA isoforms. These
mRNAs were identified as an mRNA lacking exon 14a, a full-
length mRNA containing the premature UAG stop codon, and a
third mRNA lacking the three nucleotides encoding the UAG stop
codon.
Figure 1. Pedigree and genotype of the patients. (A) Family pedigree. Identified carriers are indicated in half blackened symbols and CF
patients in blackened symbols. Consanguinity between individuals III4 and III5 is highlighted with a double line. (B) Sequence analysis performed on
the genomic DNA from a healthy control and patient III10.
doi:10.1371/journal.pgen.1001153.g001
Author Summary
Mild disease outcomes associated with premature termi-
nation codons can result from at least three different
mechanisms, but none of these mechanisms explain the
mild phenotype observed in some patients. Subtle
differences in alternative transcripts have recently been
reported at NAGNAG tandem acceptor motifs, which can
be detected in 30% of human genes. We provide the first
experimental evidence of premature termination codon
removal by alternative splicing at a NAGNAG acceptor
splice site. Our study emphasizes the biological signifi-
cance of such alternative splicing in the context of disease-
causing mutations and defines a new phenotype-modify-
ing mechanism that buffers nonsense mutations.
Alternative Splicing at a NAGNAG Site Removes PTC
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To investigate whether the alternative splicing was due to the
2623G.T mutation, we constructed a hybrid minigene contain-
ing CFTR exon 14a and approximately 400 nucleotides of its
flanking intronic regions. After transfection in the bronchial
epithelial cell line BEAS-2B, RT-PCR samples were separated by
capillary electrophoresis analysis and isoforms were identified by
sequencing. As in the direct transcript analysis, the wild-type
construct revealed a low level of exon 14a skipping (7%60.8%).
The 2623G.T substitution increased exon 14a skipping up to
92%62%. In addition, two peaks could be detected corresponding
to full-length mRNA (7%62%) and to the isoform lacking three
nucleotides (0.8%.60.5%) (Figure 3A and 3C). To focus on these
two lower abundance isoforms, a reverse primer within exon 14a
was used to amplify mRNAs containing exon 14a specifically. A
single peak was detected in mRNA obtained from cells transfected
with the wild-type construct, whereas two peaks were detected in
mRNA from cells transfected with the 2623G.T construct. The
major peak corresponded to full-length mRNA containing the
UAG stop codon (88%60.5%) and the mRNA in the minor peak
lacked these three nucleotides (12%60.5%) (Figure 3B and 3C).
The ratio between these two isoforms was comparable using either
reverse primer. The relative amounts of the three isoforms differed
from the amounts measured for endogenous CFTR, but the
minigene construct containing the mutated exon 14a sequence
reproduced the in vivo splicing pattern. Therefore, the single
nucleotide substitution (2623G.T) is the main determinant of
alternative splicing at this site.
Identification of a functional CFTR protein isoform
Recognition of the 39 splice site upstream of exon 14a generates
full-length mRNA leading to synthesis of the entire CFTR protein.
The CFTR channel is composed of two transmembrane spanning
domains, two nucleotide binding folds, and a regulatory domain
(R domain). The regulatory domain is encoded by exon 13
(orange) and exon 14a encodes the region linking the regulatory
domain to the seventh transmembrane segment (blue) (Figure 4A).
The 2623G.T mutation which occurs at the first base of exon 14a
induced multiple splicing defects, including exon skipping. An
mRNA lacking exon 14a encodes a protein missing the linker
domain between the R domain and the seventh transmembrane
segment (CFTR-del831-873, Figure 4B). In addition to the full-
length mRNA containing the UAG stop codon, alternative
splicing at the NAGNAG site generated an mRNA lacking this
stop codon. The resulting proteins would be either truncated after
the regulatory domain (CFTR-E831X, Figure 4C) or missing one
amino acid (CFTR-DE831, Figure 4D), respectively.
The processing of CFTR can be assessed by examining its
glycosylation state [15]. Western blot analysis of wild-type CFTR
protein, transiently (Figure 5A, left panels) or stably (Figure 5A, right
panel) expressed in HEK293 cells, revealed two bands. The diffuse
band of 170 kDa (band C) corresponds to the mature, fully
glycosylated protein and the thin band of approximately 140 kDa
(band B) represents the core-glycosylated immature CFTR. Similar
analysis of transiently expressed CFTR-del831-873 revealed a unique
thin band indicating a maturation defect (Figure 5A, higher left panel)
that was further investigated using an N-Glycosidase F assay (Figure
S1). After enzymatic treatment of CFTR-WT, both bands B and C
were converted to the lower apparent molecular weight non-
glycosylated band A. CFTR-del831-873 was not affected by the
enzymatic treatment, indicating an absence of glycosylation of this
protein, thus identifying the first naturally occurring non-glycosylated
CFTR mutant.
Stably expressed CFTR-E831X protein was detected as a single
band at the expected size (Figure 5A, right panel), while transiently
expressed CFTR-DE831 showed a normal maturation profile with
the presence of both bands B and C (Figure 5A, lower left panel).
Immunostaining of transiently transfected HeLa cells confirmed a
processing defect in both the CFTR-del831-873 and CFTR-
E831X mutant proteins as they could only be detected in
intracellular compartments close to the nucleus, whereas both
CFTR-WT and CFTR-DE831 showed clear cell surface staining
(Figure 5B). Finally, functional assays showed the absence of
CFTR-dependent anion transport in cells expressing either
CFTR-del831-873 or CFTR-E831X. In contrast, a high level of
anion transport was observed with CFTR-WT and CFTR-DE831,
in accordance with the biochemical and immunocytochemical
results above (Figure 5C and 5D). Therefore, we conclude that
CFTR-DE831 represents the functional form accounting for the
mild phenotype observed within this family.
Phenotypes associated with the E831X mutation
CFwassuspectedinthefirstyearoflifeinpatientIII10(Figure1A)
due to recurrent bronchitis, and this was confirmed by a positive
sweat test (70 mmol/L). The patient was tested and found to be
homozygousforthe nonsensemutation E831X.After familial study,
CF was diagnosed in his 18-year-old sister (III5), who also had a
positive sweat test and the same genotype. However, the two
siblings, now aged 13 and 30, arein good health withno evidence of
pancreatic insufficiency, and have normal lung function tests. The
female patient married her first cousin who was found to be an
E831X carrier. Their son (IV1) is homozygous for the E831X
mutation. Now 5 years of age, he presents with a positive sweat test
(74 mmol/L), but yearly clinical assessments are normal (Table 1).
Interestingly, this mutation was first described in a female CF
patient carrying the severe missense substitution G551D on the
other allele. E831X was considered as a severe mutation because
she presented with meconium ileus at birth, a neonate pulmonary
infection and an elevated sweat test [16]. Given our results, we
requestedyearlyclinicalassessments,whichindicatednopulmonary
exacerbation, an almost normal chest radiograph, moderate
pancreatic insufficiency and normal abdominal ultrasound. Thus,
her clinical outcome was better than expected at birth. This
mutationwasalsoreported intwo13-year-oldmaletwinsofTurkish
origin carrying an in-frame deletion on the other allele (591del18)
[17]. These twins had persistent nasal polyps and elevated sweat
tests, but no pancreas or lung involvement [17]. Subsequently,
E831X was reported to be the allele present in cohorts of men with
Figure 2. Direct transcript analysis. (A) qRT-PCR analysis performed on total RNA obtained from nasal epithelial cells of patient III10 or three
healthy controls. Levels were normalized to the amount of KRT18 and compared to the normalized level of the control individuals. Data represent the
mean6SE of at least two independent measurements performed in triplicate. (B) An example of capillary electrophoresis analysis of RT-PCR products
obtained after 30 cycles from control samples (n=3) or patient III10. The corresponding size and relative amount of each peak are indicated. The peak
size corresponds, respectively, to exon 14a skipped mRNA (276 bp), to full-length mRNA (396 bp), and to the mRNA lacking the UAG stop codon
(393 bp). (C) RT-PCR performed with a forward primer in exon 13 and reverse primer within exon 17 on RNA from patient III10 and a healthy donor.
Sequences were obtained from the excised band denoted 14a-. ‘‘H’’ designates the homoduplex bands of both 14a+ isoforms and ‘‘h’’ the
heteroduplex bands. (D) RT-PCR performed with a reverse primer within exon 14a and forward primer in exon 13 on RNA from patient III10 and a
healthy donor. Sequences were obtained from the excised homoduplex band (‘‘H’’); ‘‘h’’ designates heteroduplex bands.
doi:10.1371/journal.pgen.1001153.g002
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was purified from BEAS-2B cells transfected with empty plasmid (pET01), minigene containing exon 14a (WT) or mutant exon 14a (2623G.T). RT-PCR
was performed using a FAM-labeled forward primer located within the splice donor exon and a reverse primer within the splice acceptor exon of the
pET01 plasmid. The corresponding size and relative amount of each peak is indicated. The peak at 245 bp corresponds to exon 14a skipped mRNA, at
374 bp to full-length mRNA and at 371 bp to mRNA lacking the UAG stop codon. (B) Examples of capillary electrophoresis analysis of RT-PCR
products obtained with a FAM-labeled forward primer located within the splice donor exon of the pET01 plasmid and a reverse primer within exon
14a. The corresponding size and relative amount of each peak are indicated. The peak at 183 bp corresponds to full-length mRNA and at 180 bp to
the mRNA lacking the UAG stop codon. (C) Sequences were obtained using unlabeled forward primer using the 21 cycle RT-PCR products from (B).
doi:10.1371/journal.pgen.1001153.g003
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allele [18–20]. These clinical observations and our data bring the
deleterious nature of the E831X mutation into question; but how
can the minor functional CFTR-DE831 isoform lead to such mild
phenotypes? The minimal level of CFTR mRNA required to
maintain normal function differs between organs, with the vas
deferens beingthe most sensitivetissue [21]. CFTR-DE831 mRNAs
did not appear to reach this threshold in all tissues, leading to mild
phenotypes such as nasal polyposis or CBAVD in compound
heterozygotes. In the nasal epithelial cells of patient III10, mRNAs
encoding functional CFTR-DE831 were estimated at 8%. As total
CFTR transcripts were reduced to 48% compared to WT levels, this
amount can be corrected down to 4%, a level comparable to
previousstudies associated with mild lungdisease[22,23].However,
the relative level of each transcript may differ between patients, as
the same PTC has been shown to elicit NMD with variable
efficiency in CF nasal epithelial cells, thus reducing the amount of
full-length mRNA containing the stop codon [13].
Analysis of the splice site context in the case of a
NAGNAG motif
The intron 13/exon 14a boundary, illustrated in Figure 6,
shows the presence of a proximal acceptor site in the intron and a
distal acceptor site in the exon, typical of a NAGNAG motif. The
use of the proximal or distal acceptor site is regulated by multiple
factors. First, the strength of the acceptor site depends on the site
itself (CAG.TAG.AAG), the polypyrimidine tract, and the
branch point sequences. In addition, the branch point sequence-
to-NAGNAG region in the 39 tandem splice site was shown to
participate in 39 splice-site selection [24]. This selection could also
be modulated by RNA-binding proteins because exonic or intronic
splicing enhancer (ESE, ISE) and silencer (ESS, ISS) sites have
been described as overabundant in the vicinity of tandem 39 splice
sites compared to constitutively spliced exons [25]. Lastly, the
nucleotides composing the NAGNAG acceptor site are also tightly
implicated in the recognition of either the proximal or distal splice
site. NAGNAG acceptor sites have been classified with respect to
their splicing plausibility. Plausible sites allow the use of both
acceptor sites, whereas implausible ones allow the use of a single
site [26]. The 2623G.T substitution converts the NAGNAG
acceptor motif from an implausible CAGGAG (use of the
proximal site) into a plausible CAGTAG motif (use of either
proximal or distal splice sites). Therefore, the mutation would
favor the use of the distal splice site, resulting in bypass of the PTC
and explaining the mechanism leading to an mRNA lacking three
nucleotides (Figure 6).
Figure 4. A single nucleotide substitution generating three distinct proteins. (A) CFTR-WT processing from DNA to protein. The R domain is
encoded by exon 13 (orange), whereas exon 14a encodes the region linking the R domain to the seventh transmembrane segment (blue). The two
glycosylation sites are indicated between the seventh and eighth transmembrane segment. The 2623G.T mutation located at the first nucleotide of
exon 14a induces skipping of exon 14a producing CFTR-del831-873 (B). Alternative splicing at the NAGNAG site generates mRNA including the stop
codon encoding truncated CFTR-E831X (C), and mRNA lacking the stop codon leading to CFTR-DE831 (D).
doi:10.1371/journal.pgen.1001153.g004
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NAGNAG motifs (BayNAGNAG) [27] predicted a shift in the
probability of using both the proximal and distal acceptor sites
from 0.2% to 81.2%, consistent with our in vivo results (Table 2).
The first description of a disease-causing mutation in a NAGNAG
splice site was reported in the ABCA4 gene [8], before the
description of the NAGNAG motif by Hiller et al. in 2004 [5]. This
mutation (2588G.C) was shown to produce two isoforms leading
to either an indel of Gly863 or to a missense defect, Gly863Ala, by
shifting the NAGNAG motif from an implausible sequence
(TAGGAG) into a plausible sequence (TAGCAG). Similarly, in
silico analysis predicted an increase in the probability of using
either distal or proximal acceptor sites from 0.1% to 57.7%
(Table 2). Our study demonstrated that disease-causing mutations
in NAGNAG are predictive of alternative splicing, as previously
proposed for single nucleotide polymorphisms in NAGNAG
acceptors [26]. Therefore, in the absence of mRNA samples,
such splicing events could be anticipated by in silico
analysis.
The removal of a deleterious PTC could apply to many genes,
as the configuration we have described is frequent in the human
genome. Indeed, NAGGAG represents the most frequent
NAGNAG motif recognizable upstream of a coding exon [5].
Querying the TassDB retrieved 4882 occurrences of the
NAGGAG motif with GAG in a coding exon, representing 4597
genes. Among these NAGGAG motifs, 52.2% (n=2551) are in
intron phase 0, a configuration that leads to the first amino acid of
the exon being a Glu, as shown in this study. We can therefore
hypothesize that bypass of a deleterious PTC could occur when
similar GAG to TAG mutations affect one of the 2551 NAGGAG
motifs within the human genome.
Concluding remarks
In addition to contributing to proteome plasticity [9], alternative
splicing at tandem 39 acceptor sites can also result in in vivo removal
of a premature UAG stop codon. This feature differentiates the
UAG stop codon from UAA or UGA and may help explain
phenotype/genotype discrepancies. The novel PTC removal
Figure 5. Characterization of the three CFTR mutant proteins. (A) Western blot analysis of HEK293 cells transiently transfected with CFTR-WT,
CFTR-del831-873 (upper left panel), or CFTR-DE831 (lower left panel). Western blot analysis of HEK293 cells stably expressing CFTR-WT or CFTR-E831X
(right panel). Filled and empty arrowheads indicate the fully-glycosylated (170 kDa) and core-glycosylated (140 kDa) CFTR, respectively. Grey
arrowheads indicate mutant proteins. (B) Immunostaining performed on HeLa cells transiently transfected with the indicated constructs. CFTR was
stained with MM13-4 anti-CFTR and an AlexaFluor 488 conjugated secondary antibody (green), nuclei were visualized using DAPI (blue). Scale bars:
10 mm. (C) Representative cell fluorescence recordings from HEK293 cells transiently expressing the halide-sensitive YFP (scale bar reports the
percentage of total cell fluorescence). Extracellular addition of I
2 (arrow) caused YFP quenching with a rate proportional to the rate of I
2 influx and
CFTR activity. (D) Summary of data obtained from the functional assay reporting rates of I
2 transport for the indicated constructs in HEK293 cells. The
bars report the transport of iodide as determined from the maximal rate of cell fluorescence decrease (mean6SE, n=8–12).
doi:10.1371/journal.pgen.1001153.g005
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deletion ofa single amino acid being potentially lessdeleterious than
a truncating mutation. This study also emphasizes the biological
significance of alternative splicing at tandem acceptor sites in the
contextofdisease-causing mutations.Subtle splicing eventscould be
considered simply as noise tolerated by the cell [28]; however,
considering point mutations at NAGNAG acceptor sites clearly
provides evidence of their functional relevance. Alternative splicing
at these acceptor sites could define a novel phenotype-modifying
mechanism buffering deleterious nonsense mutations. Overall, this
study highlights the importance of thoroughly characterizing the
molecular defects in patients with milder than expected phenotypes.
Indeed, such molecular studies can reveal naturally occurring
mechanisms where modifier genes or epigenetic factors have been
suspected to have an effect.
Materials and Methods
Ethics statement
Informed consent was obtained from all subjects and the local
ethics committee approved the study.
mRNA purification
Cells obtained from nasal brushings were immediately trans-
ferred into RNA-Later buffer (Qiagen) and total RNA was purified
as recommended by the manufacturer using QiaQuick Spin
columns (Qiagen). Two independent RT-PCR assays were
performed with 400 ng of total RNA for each sample (Applied
Biosystems).
Quantitative real-time PCR assays
CFTR and KRT18 primers and probes (TaqMan FAM/NFQ-
MGB probe format) were designed by Applied Biosystems. PCR
reactions contained the TaqMan Gene Expression Assay Mix,
TaqMan Universal PCR Master Mix, no AmpErase UNG, and
1 ml cDNA (or 1 ml of DNase/RNase free water for the No
Template Control) in a final volume of 20 ml. Samples were placed
in 96-well plates and amplified in an ABI 7900HT Sequence
Detection System (Applied Biosystems). Amplification conditions
were 10 min at 95.0uC, followed by 40 cycles of 15 s at 95.0uC
and 1 min at 60.0uC. All reactions were run in triplicate and each
sample was run in two QPCR assays. To correct for variations in
the amount of input RNA and efficiency of the reverse
transcription, KRT18 (which is specifically expressed in ciliated
and secretory epithelial cells) was quantified and results were
normalized to these values. Relative amounts of CFTR mRNA
were measured using the 2
2DDCT method [29]. A control sample
was chosen as a calibrator, i.e., as the baseline for the comparative
results.
Experimental validation and quantification of splice
variants
Semi-quantitative RT-PCRs were performed using 1 ml cDNA
templates with a sense FAM-labeled primer in exon 13 (59-
AGTGTCACTGGCCCCTCAG-39) and a reverse primer in
exon 17 (59-GTGTCGGCTACTCCCACGTA-39) or in exon 14a
(59-CATGTAGTCACTGCTGGTATGCT-39)i na2 0 ml total
volume. PCR conditions were 94uC for 5 min followed by linear
phase amplification of 29 cycles or 30 cycles at 94uC for 20 sec,
60uC for 20 sec, and 72uC for 20 sec. All samples were then
extended at 72uC for 1 min and, finally, cooled to 4uC in a 9700
thermocycler (Applied Biosystems). Capillary electrophoresis
Table 1. Phenotypes associated with E831X mutations.
Age at diagnosis,
gender: M, F Ethnic origin Genotype
Sweat test
*
(mmol/l) Phenotype References
Birth, F - E831X/G551D 100 Early childhood: MI, PI, and lung infections
Adulthood: PI and no pulmonary symptoms
15
Twins 13y, M Turkish E831X/591del18 89/94 Recurrent nasal polyps 16
Adult, M Turkish E831X/D110H - CBAVD 17
Adult, M Turkish E831X/1677delTA - CBAVD 17
Adult, M Turkish E831X/DF508 92/94 CBAVD
PS and mild lung disease
18
Adult, M Portuguese E831X/DF508 - CBAVD 19
First year, F - E831X/DF508 100 PS and no lung involvement French registry
First year, M Turkish E831X/E831X 70 PS and mild lung disease This study III10
Adult, F Turkish E831X/E831X 70 PS and no lung involvement This study III5
Neonatal diagnosis, M Turkish E831X/E831X 74 PS and mild lung disease This study IV1
Abbreviations: CBAVD, congenital bilateral absence of the vas deferens; MI, meconium ileus; PI, pancreatic insufficiency; PS, pancreatic sufficiency.
*Sweat test: normal values ,30 mmol/l and border line values 30–60 mmol/l.
doi:10.1371/journal.pgen.1001153.t001
Figure 6. Schematic representation of the intron 13/exon 14a
junction. Proximal and distal acceptor sites (AS) are indicated both on
the WT and 2623G.T sequences. The tandem splice acceptor site is
highlighted in bold. A broken line represents splicing events.
doi:10.1371/journal.pgen.1001153.g006
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mixture (1/40) added to 18.5 ml of formamide and 0.1 ml of ROX
400 HD fluorescent size standards (Applied Biosystems). The
mixture was then denatured at 95uC for 5 min and cooled to 4uC.
Amplified products were separated on an ABI 3130 XL DNA
analyzer using 3130 POP6 and analyzed with the GeneMapper
4.0 software (Applied Biosystems). Ratios of splicing isoforms were
determined as the peak area for the CFTR isoform divided by the
total peak areas for the three isoforms. Data represent the
mean6SE of at least two independent measurements performed in
triplicate.
Sequencing of mRNA isoforms
For sequencing of the different splice variants, PCR was
performed using 1 ml of cDNA templates with a sense primer in
exon 13 (59-AGTGTCACTGGCCCCTCAG-39) and a reverse
primer in exon 17 (59-GTGTCGGCTACTCCCACGTA-39)o r
in exon 14a (59-CATGTAGTCACTGCTGGTATGCT-39) using
the same conditions as described previously for 40 cycles.
Following RT-PCR, products were resolved on a 2% agarose
gel and bands of interest were excised and purified using a gel
extraction kit (Promega). Samples were subsequently sequenced
using both forward and reverse primers.
Cell culture and transfection
HEK293 and HeLa cells were grown at 37uC, 5% CO2 in
DMEM medium supplemented with 10% SVF and 1% PS.
BEAS-2B cells (CRL-9609) cells were grown in LHC-8 medium
supplemented with 10% fetal calf serum and 1% Penicillin
Streptomycin. Cells were transfected with Lipofectamine 2000
according to the manufacturer’s instructions. HEK293 cells stably
expressing CFTR-WT or CFTR-E831X were selected using
Zeocin (50 mg/mL).
Constructs and mutagenesis
CFTR-WT cDNA was subcloned in pTracer [30] and CFTR-
E831X, CFTR-DE831 and CFTR-del-831-873 were generated by
site-directed mutagenesis (Stratagene) and each construct was
sequenced. A fragment comprising exon14a, 387 bp of the
upstream intron 13 and 371 bp of the downstream intron 14a
was PCR amplified from genomic DNA obtained from a healthy
volunteer or from patient III10 using the following primers: 59-
GGACCCCTGAAGAAACAGGT-39 and 59-GCCTTCTA-
CTTTGAGCTTTCG-39. PCR products were subcloned into
pCR II (Invitrogen) and inserts sequenced before subcloning into
the pET01 vector (Mobitec) at the BamHI and XbaI restriction
sites.
Hybrid minigene splicing assays
Minigenes containing either the exon 14a-WT or the 2623G.T
mutation and flanking introns (387 bp upstream and 371 bp
downstream of exon 14a) were transfected in BEAS-2B cells
seeded in 6-well plates. Total RNA was purified as recommended
by the manufacturer using QiaQuick Spin columns (Qiagen). The
mRNA concentrations were measured using a NanoDrop
spectrophotometer. The mRNA (1.5 mg in a final volume of
20 ml) was DNAse treated for 30 min at 37uC before heat
denaturation of the enzyme (Quiagen). Treated mRNA (400 ng)
was used to perform RT-PCR using the High capacity cDNA
Reverse Transcription kit (Applied Biosystems). Ten percent of the
RT-PCR product was PCR amplified using primers specific to the
splice donor and splice acceptor exons of the pET01 plasmid (59-
FAM-GTGACAGCTGCCAGGATCG-39 and 59-CAGTGC-
CAAGGTCTGAAGGT-39). PCR was conducted at 94uC for
5 min followed by linear phase amplification of 20 cycles or 21
cycles at 94uC for 20 sec, 60uC for 20 sec, and 72uC for 20 sec. All
samples were then extended at 72uC for 1 min and, finally, cooled
to 4uC in a 9700 thermocycler (Applied Biosystems). Capillary
electrophoresis analysis of the PCR products was performed as
previously described. Ratios of splicing isoforms were determined
as the peak area of the considered isoform divided by the total
peak areas. Sequencing was performed on the 21 cycle PCR
products generated with the internal primer using an unlabeled
forward primer located within the splice donor exon of the pET01
plasmid. Data represent the mean6SE of at least two independent
measurements performed in duplicate.
IP and WB analysis
HEK293 cells were plated on 100 mm dishes and transiently
transfected with CFTR-WT, CFTR-del831-873 or CFTR-DE831.
Immunoprecipitation was performed as previously described [31]
with a C-terminal directed anti-CFTR antibody (24-1, R&D
systems). Cells stably expressing CFTR-E831X or CFTR-WT
were lysed in 1X RIPA buffer and samples containing 30 mg total
protein were analyzed by Western blot. After gel electrophoresis
and transfer, membranes were probed using the MM13-4
antibody (Millipore) directed against the N-terminal region of
CFTR. Direct recording of the chemiluminescence was performed
using the CCD camera of the GeneGnome analyzer and
quantification using the GeneTools software (Syngene BioImaging
Systems, Synoptics Ltd).
N-Glycosidase F treatment
HEK293 cells were plated on 60 mm dishes and transiently
transfected with CFTR-WT or CFTR-del831-873. Cells were
washed twice with ice cold PBS and lysed in N-Glycosidase F
buffer containing 20 mM sodium phosphate, pH 7.5, 0.1% SDS,
50 mM b-mercaptoethanol, and 1% Igepal, supplemented with
protease inhibitors. N-Glycosidase F (3 Units, Roche) was added to
lysates and incubated overnight at 37uC and one tenth of the
volume of each sample was analyzed by Western blot.
Table 2. In silico analysis using BayNAGNAG software.
Probability of using
proximal acceptor site
Probability of using
distal acceptor site
Probability of using
both acceptor sites
WT MUT
* WT MUT
* WT MUT
*
CFTR gene 99.8% 17.1% 0 1.7% 0.2% 81.2%
ABCA4 gene 99.8% 39.9% 0 2.3% 0.1% 57.7%
*MUT=2623G.T in the CFTR gene and 2588G.C in the ABCA4 gene.
doi:10.1371/journal.pgen.1001153.t002
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HeLa cells were seeded on glass coverslips and transfected with
the appropriate construct. The following day, cells were fixed
using ice-cold methanol. Cells were permeabilized (1% BSA, 0.1%
TritonX-100 in PBS) and, then, incubated with the primary
antibody, MM13-4 anti-CFTR, diluted 1/200, for 2 h at room
temperature. Secondary antibody (1/500 dilution, AlexaFluor 488
conjugated, Invitrogen) was then added and incubated 1 h.
Coverslips were mounted using Vectashield mounting medium
containing DAPI (4, 6-Diamino-2-phenylindol) and analyzed using
a Leica DMR epifluorescence microscope.
YFP-based functional assays
CFTR activity was determined in transiently transfected
HEK293 cells using the halide-sensitive yellow fluorescent protein
YFP-H148Q/I152L as described previously [32]. Cells were
plated in 96-well microplates (2.5610
4 cells/well) and co-
transfected with CFTR and halide-sensitive YFP. The CFTR
functional assay was carried out 48 h after transfection. Cells were
incubated for 30 minutes with PBS containing forskolin (20 mM)
before being transferred to an Olympus IX 50 fluorescence
microscope (Chroma; excitation: HQ500/20X; emission:
HQ535/30M; dichroic: 515 nm), equipped with a photomultiplier
tube (Hamamatsu) for detection of fluorescence. Cell fluorescence
was continuously measured before and after addition of NaI (final
NaI concentration: 100 mM). The signal was digitized using a
PowerLab 2/25 acquisition system (ADInstruments). Cell fluores-
cence recordings were normalized to the initial average value
measured before addition of NaI. Signal decay was fitted to a
double exponential function to derive the maximal slope
corresponding to initial influx of I
2 into the cells. Maximal slopes
were converted to rates of change in intracellular I
2 concentration
(in mM/s) using the equation: d[I
2]/dt=KI[d(F/F0)/dt] where
KI is the affinity constant of YFP for I
2 and F/F0 is the ratio of the
cell fluorescence at a given time vs. initial fluorescence [33].
In silico analysis
Bayesian network predictions of splicing outcomes at NAGNAG
tandem acceptors in wild-type and mutant conditions were
calculated using the BayNAGNAG software, (http://www.
tassdb.info/baynagnag/form.html).
TassDB queries
Query for the number of genes containing a NAGGAG motif:
SELECT count(distinct GeneID) FROM Gene G, Transcript
T, SS2Transcript2SED SS2Tr2SED, SpliceSite SS, SpliceEvent-
Data SED WHERE G.ID=T.GeneID AND T.ID=SS2Tr2-
SED.TranscriptID AND SS2Tr2SED.SpliceSiteID=SS.ID AND
SS2Tr2SED.SpliceEventDataID=SED.ID AND SS.Type=‘ac-
ceptor’ AND SED.NumEESTs.=0 AND SED.NumIESTs.=0
AND ((SS.pattern=‘CAGGAG’) OR (SS.pattern=‘TAGGAG’)
OR (SS.pattern=‘AAGGAG’) OR (SS.pattern=‘GAGGAG’))
AND G.species=‘Homo sapiens’. Query for the number of genes
having a NAGGAG motif with the GAG within the coding exon:
SELECT count(distinct GeneID) FROM Gene G, Transcript
T, SS2Transcript2SED SS2Tr2SED, SpliceSite SS, SpliceEvent-
Data SED WHERE G.ID=T.GeneID AND T.ID=SS2Tr2-
SED.TranscriptID AND SS2Tr2SED.SpliceSiteID=SS.ID AND
SS2Tr2SED.SpliceEventDataID=SED.ID AND SS.Type=‘ac-
ceptor’ AND SED.NumEESTs.=1 AND SED.NumIESTs=0
AND ((SS.pattern=‘CAGGAG’) OR (SS.pattern=‘TAGGAG’)
OR (SS.pattern=‘AAGGAG’) OR (SS.pattern=‘GAGGAG’))
AND G.species=‘Homo sapiens’;
Query for the number of genes having a NAGGAG motif with
the GAG within the coding exon and with the intron phase=0:
SELECT count(distinct GeneID) FROM Gene G, Transcript
T, SS2Transcript2SED SS2Tr2SED, SpliceSite SS, SpliceEvent-
Data SED WHERE G.ID=T.GeneID AND T.ID=SS2Tr2-
SED.TranscriptID AND SS2Tr2SED.SpliceSiteID=SS.ID AND
SS2Tr2SED.SpliceEventDataID=SED.ID AND SS.Type=‘ac-
ceptor’ AND SED.NumEESTs.=1 AND SED.NumIESTs=0
AND ((SS.pattern=‘CAGGAG’) OR (SS.pattern=‘TAGGAG’)
OR (SS.pattern=‘AAGGAG’) OR (SS.pattern=‘GAGGAG’))
AND SED.phaseUTR like ‘intron phase 0’ AND G.specie-
s=‘Homo sapiens’.
Supporting Information
Figure S1 Characterization of the glycosylation pattern of
CFTR-del831-873 protein. Western blot analysis of HEK293
cells transiently transfected with CFTR-WT, CFTR-del831-873,
or with the empty vector (mock). Lysates were incubated in the
presence (+) or absence (2) of N-Glycosidase F. Filled, empty and
shaded arrowheads indicate the fully-glycosylated (C band), core-
glycosylated (B band) and non-glycosylated (A band) CFTR,
respectively. Grey arrowhead indicates mutant protein.
Found at: doi:10.1371/journal.pgen.1001153.s001 (0.33 MB
TIF)
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